Table S1. Clinicopathologic association of PD-L1 (22C3) expression in TCs and TILs

Parameters	PD-L1 (22C3) in TCs			PD-L1 (22C3) in TILs		
	Negative	Positive	P	Negative	Positive	P
Age			0.868			0.546
≤60	11 (47.8%)	12 (52.2%)		11 (47.8%)	12 (52.2%)	
>60	20 (50.0%)	20 (50.0%)		16 (40.0%)	24 (60.0%)	
Sex			0.244			0.769
Male	11 (47.8%)	16 (59.3%)		11 (40.7%)	16 (59.3%)	
Female	20 (55.6%)	16 (44.4%)		16 (44.4%)	20 (55.6%)	
Melanoma subtype			0.017			0.068
Acral	19 (65.5%)	10 (34.5%)		16 (55.2%)	13 (44.8%)	
Non-acral	12 (35.2%)	22 (64.7%)		11 (32.4%)	23 (67.6%)	
cN stage (n = 58)			0.662			0.848
N0	20 (46.5%)	23 (53.5%)		16 (37.2%)	27 (62.8%)	
N+	6 (40.0%)	9 (60.0%)		6 (40.0%)	9 (60.0%)	
cM stage (n = 58)			0.738			0.732
M0	22 (46.8%)	25 (53.2%)		17 (36.2%)	30 (63.8%)	
M+	4 (36.4%)	7 (63.6%)		5 (45.5%)	6 (54.5%)	
Lymphovascular invasion			0.257			0.128
Absent	26 (46.4%)	30 (53.6%)		22 (39.3%)	34 (60.7%)	
Present	5 (71.4%)	2 (28.6%)		5 (71.4%)	2 (28.6%)	
Ulceration (n = 31)			0.809			0.707
Absent	10 (50.0%)	10 (50.0%)		10 (50.0%)	10 (50.0%)	
Present	5 (45.5%)	6 (54.6%)		4 (36.4%)	7 (63.6%)	
Breslow thickness (n = 35)			1.000			1.000
<1mm	4 (44.4%)	5 (55.6%)		3 (33.3%)	6 (66.7%)	

≥1mm	10 (38.5%)	16 (61.5%)		9 (34.6%)	17 (65.4%)
BRAF mutation			0.414			0.798
Absent	25 (52.1%)	23 (47.9%)		21 (43.8%)	27 (56.3%)
Present	6 (40.0%)	9 (60.0%)		6 (40.0%)	9 (60.0%)

Table S2. Clinicopathologic association of PD-L1 (E1L3N) expression in TCs and TILs

Parameters	PD-L1 (E1L3N) in TCs			PD-L1 (E1L3N) in TILs		
	Negative	Positive	*P*	Negative	Positive	*P*
Age			0.520			0.946
≤60	9 (39.1%)	14 (60.9%)		9 (39.1%)	14 (60.9%)	
>60	19 (47.5%)	21 (52.5%)		16 (40.0%)	24 (60.0%)	
Sex			1.000			0.882
Male	12 (44.4%)	15 (55.6%)		11 (40.7%)	16 (59.3%)	
Female	16 (44.4%)	20 (55.6%)		14 (38.9%)	22 (61.1%)	
Melanoma subtype			0.037			0.020
Acral	17 (58.6%)	12 (41.4%)		16 (55.2%)	13 (44.8%)	
Non-acral	11 (32.4%)	23 (67.6%)		9 (26.5%)	25 (73.5%)	
cN stage (n = 58)			0.975			0.788
N0	17 (39.5%)	26 (60.5%)		16 (37.2%)	27 (62.8%)	
N+	6 (40.0%)	9 (60.0%)		5 (33.3%)	10 (66.7%)	
cM stage (n = 58)			1.000			0.729
M0	19 (40.4%)	28 (59.6%)		18 (38.3%)	29 (61.7%)	
M+	4 (36.4%)	7 (63.6%)		3 (27.3%)	8 (72.7%)	
Lymphovascular invasion			0.690			0.421
Absent	24 (42.9%)	32 (57.1%)		21 (37.5%)	35 (62.5%)	
Present	4 (57.1%)	3 (42.9%)		4 (57.1%)	3 (42.9%)	
Ulceration (n = 31)			0.718			0.275
Absent	9 (45.0%)	11 (55.0%)		10 (50.0%)	10 (50.0%)	
Present	4 (36.4%)	7 (63.6%)		3 (27.3%)	8 (72.7%)	
Breslow thickness (n = 35)			1.000			0.416
<1mm	3 (33.3%)	6 (66.7%)		4 (44.4%)	5 (55.6%)	

≥1mm	8 (30.8%)	18 (69.2%)		7 (26.9%)	19 (73.1%)
BRAF mutation			0.691			0.565
Absent	22 (45.8%)	26 (54.2%)		20 (41.7%)	28 (58.3%)
Present	6 (40.0%)	9 (60.0%)		5 (33.3%)	10 (66.7%)